SCHEMBL29616231

SCHEMBL29616231

CCOC(=O)[C@@H]1C[C@@H]1c1cc(N)c(C(F)(F)F)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.38
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 3/20 0.37
TSHR P16473 3/20 0.36
MAPK1 P28482 1/20 0.36
DPP4 P27487 1/20 0.35
HPGD P15428 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28685857 1.00 HSD11B1 (0.38) HSD11B1KDM4EALDH1A1TSHRMAPK1
SCHEMBL18541984 0.79 KDM4E (0.38) KDM4EALDH1A1MAPTCA12CA1
SCHEMBL28679712 0.79 KDM4E (0.41) KDM4EALDH1A1MAPTCA12CA1
SCHEMBL29616354 0.79 KDM4E (0.41) KDM4EALDH1A1MAPTCA12CA1
SCHEMBL28702448 0.77 CA1 (0.37) HSD11B1KDM4EALDH1A1TSHRDPP4
SCHEMBL31406356 0.77 SLC9A1 (0.43) HSD11B1KDM4EALDH1A1TSHRDPP4
SCHEMBL13043472 0.77 DPP4 (0.46) HSD11B1KDM4EALDH1A1TSHRMAPK1
SCHEMBL13043587 0.75 CA1 (0.39) KDM4EALDH1A1TSHRHPGDMEN1
SCHEMBL2141354 0.74 HTR2A (0.47) KDM4EALDH1A1TSHRMAPK1DPP4
SCHEMBL15669103 0.73 DPP4 (0.44) KDM4EALDH1A1TSHRMAPK1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630510-B2 EP2 antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 US disclosed
EP-3992176-B1 EP2 ANTAGONIST ONO PHARMACEUTICAL CO (JP) 2025-08-27 EP disclosed
US-20220388955-A1 EP2 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2022-12-08 US disclosed
EP-3992176-A1 EP2 ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2022-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220388955-A1 EP2 ANTAGONIST PTGER2, PTGER1, PTGES2 HSD11B1 828/4885KDM4E 4168/4885ALDH1A1 1473/4885
US-12630510-B2 EP2 antagonist PTGER2, PTGER1, PTGER4 HSD11B1 617/4885KDM4E 3811/4885ALDH1A1 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.